a combination of (i) an amount of at least one compound effective for agonizing a melanocortin-receptor selected from MC- 1 R and MC-4R, and (ii) an amount of at least one compound effective for inhibiting cAMP phosphodiesterase." Specific disclosures are only to PDE-3, -4, -7 or -8 inhibitors, and a number of specific diseases are disclosed (e.g., inflammatory bowel disease, rheumatoid arthritis, asthma, etc.), but not sexual dysfunction
With regard to measure reporting, we estimate a decrease in burden of 267 hours (3,200 HOPDs 50 percent of HOPDs 0.167 hours per HOPD) at a savings of $14,701 (267 hours $55.06/hour) for voluntary reporting for the CY 2025 reporting period and 533 hours annually (0.167 hours 3,200 HOPDs) at a savings of $29,347 (533 hours $55.06/hour) for mandatory reporting beginning with the CY 2026 reporting period
These should remain steady or improve as fat is lost
Diet and gastrointestinal bypass-induced weight loss: the roles of ghrelin and peptide YY
